Drugs / split-virion, adjuvanted H1N1 vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00975572 | Jul → Sep 2009 | influenza | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00956111 | Jul → Sep 2009 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | split-virion, adjuvanted H1N1 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00956111 ↗ |
| Modality | Vaccine | “Sinovac's split-virion or whole-virion novel influenza A (H1N1) vaccines.” NCT00956111 ↗ |
| Route | Intramuscular | “to receive intramuscular influenza H1N1 vaccine” NCT00975572 ↗ |